Characterization of PEBP1 mediated ISR.
(A) CHOP/DDIT3 expression by qPCR in trametinib-treated control and PEBP1 KO cells. (B) DDIT4 expression by qPCR in trametinib-treated control and PEBP1 KO cells. Data shown for panels C and D are mean±SD, n=3. (C) Dose dependent activation of ISR by oligomycin (0, 0.1, 0.25, 0.5, 1 and 2 µM final conc.) in RPE1 control and PEBP1 KO cells. (D) Dose-dependent activation of ISR by the iron chelator DFOM (0, 0.05, 0.1, 0.25, 0.5 and 1 mM final conc). (E) Time-course (0, 2, 4, 8, 16 and 24h) of cells treated with 0.5 µM rotenone. (F) Dose-dependent induction of ISR with poly(I:C) for 4h. The specific concentrations used were 0, 1, 5, 10, 25 and 50 µg/ml. (G) Dose-dependent activation of ISR with tunicamycin (0, 0.25, 0.5, 1, 2.5 and 5 µM final conc.) for 4h. (H) Effect of 20 µM Sephin-1 (S) and 10 µM Raphin-1 (R) phosphatase inhibitors on oligomycin induced eIF2α phosphorylation in control, PEBP1 and HRI KO cells. Phosphatase inhibitors were added 1h before adding 1 µM oligomycin, and ISR was induced for 4h before cell lysis. All experiments were repeated 2-3 times with representative data shown.